Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, novembre 20
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Halozyme Therapeutics Inc
HALO
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$92.65
-0.39
-0.42%
Ult. Agg.: Nov 20, 1:51 PM
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Halozyme Therapeutics Financials
Halozyme Therapeutics (HALO) financial statements — income, revenue, gross margin and key metrics.
PRO
Perché si muove?:
Halozyme Therapeutics shares are trading lower after the company expressed ...
Earnings & Guidance News
Nasdaq 100 Rebounds 2% After Worst Day Since 2020, Payrolls Smash Estimates: Stock Market Today
Chipmakers bounce in the stock market today after October payrolls smash estimates. Nasdaq 100 eyes its best day since Sept. 21; QQQ gains 2%.
Piero Cingari
PRO
Halozyme Therapeutics Raises FY2026 Adj EPS Guidance from $8.65-$9.00 to $8.75-$9.05 vs $8.84 Est; Raises FY2026 Sales Guidance from $1.835B-$1.910B to $1.860B-$1.925B vs $1.879B Est
Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $8.65-$9.00 to $8.75-$9.05 vs $8.84 analyst estimate. Raises FY2026 sales outlook from $1.835 billion-$1.910 billion to $1.860 billion-$1.925
Benzinga Newsdesk
PRO
Halozyme Therapeutics Q3 Adj. EPS $2.39 Beats $2.35 Estimate, Sales $492.974M Beat $491.561M Estimate
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.39 per share which beat the analyst consensus estimate of $2.35 by 1.27 percent. This is a 38.95 percent increase over earnings of $1.72 per share
Benzinga Newsdesk
PRO
Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $1.84 by 23.91 percent. This is a 48.05 percent increase over earnings of $1.54 per share
Benzinga Newsdesk
PRO
Halozyme Therapeutics Raises FY2026 Adj EPS Guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 Est; Raises FY2026 Sales Guidance from $1.710B-$1.810B to $1.835B-$1.910B vs $1.773B Est
Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 analyst estimate. Raises FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.835 billion-$1.910
Benzinga Newsdesk
PRO
Halozyme Therapeutics Affirms FY2026 Adj EPS Guidance of $7.75-$8.25 vs $8.09 Est; Affirms FY2026 Sales Guidance of $1.710B-$1.810B vs $1.760B Est
Halozyme Therapeutics (NASDAQ:HALO) affirms FY2026 Adj EPS guidance from $7.75-$8.25 to $7.75-$8.25 vs $8.09 analyst estimate. Affirms FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.710 billion-$1.810
Benzinga Newsdesk